<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003878</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067044</org_study_id>
    <secondary_id>NABTT-9802</secondary_id>
    <secondary_id>JHOC-NABTT-9802</secondary_id>
    <nct_id>NCT00003878</nct_id>
  </id_info>
  <brief_title>Carmustine Implants in Treating Patients With Brain Metastases</brief_title>
  <official_title>The Treatment of One or Two Supratentorial Brain Metastases With Surgical Resection and BCNU-Polymer Wafers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Brain Tumor Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving the drugs in different ways may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating&#xD;
      patients who have brain metastases and who are undergoing surgery to remove the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the local recurrence rate in patients with supratentorial metastatic brain&#xD;
           tumors undergoing surgical resection treated with polifeprosan 20 with carmustine&#xD;
           implant (Gliadel wafers).&#xD;
&#xD;
        -  Determine the incidence and time to recurrence at distant sites within the CNS in these&#xD;
           patients after this treatment.&#xD;
&#xD;
        -  Determine the median, 6-month, 1-year, and 2-year survival of these patients on this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the incidence and severity of cognitive function loss of these patients on&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the incidence and severity of CNS and systemic toxic effects of these patients&#xD;
           on this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive up to 8 polifeprosan 20 with carmustine implants (Gliadel wafers)&#xD;
      implanted in the resected tumor cavity.&#xD;
&#xD;
      Patients are followed on day 7 or day of discharge, at 1 month, 3 months, every 3 months for&#xD;
      21 months, and then for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polifeprosan 20 with carmustine implant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Supratentorial brain metastases for which surgery is recommended&#xD;
&#xD;
               -  Solitary, unilateral, intracranial mass consistent with metastasis on MRI scan OR&#xD;
&#xD;
               -  Two brain lesions consistent with metastases on MRI scan&#xD;
&#xD;
               -  Lesions must be accessible through a single craniotomy&#xD;
&#xD;
               -  Metastatic lesions clearly distinct from tumor bed of any benign lesions&#xD;
&#xD;
               -  Intraoperative frozen section diagnosis of metastatic tumor from CNS lesion&#xD;
&#xD;
          -  No prior malignant intracranial neoplasm&#xD;
&#xD;
          -  No lesion(s) in the brainstem&#xD;
&#xD;
          -  No open communication of the resection cavity with the ventricle following resection&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No concurrent hematologic disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No concurrent hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  No concurrent renal disease&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No concurrent cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No concurrent pulmonary disorders&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Mini mental score at least 15&#xD;
&#xD;
          -  No known hypersensitivity to carmustine or Gliadel wafers&#xD;
&#xD;
          -  No other serious concurrent medical illness or infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior cranial irradiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior surgery involving brain metastases or primary brain tumor(s) (except for&#xD;
             benign intracranial lesions such as pituitary adenoma, meningioma, or schwannoma)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent systemic therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Olivi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

